alendronate

(redirected from Binosto)
Also found in: Dictionary, Thesaurus.

alendronate

 [ah-len´dro-nāt]
a calcium-regulating agent used in the form of the sodium salt to inhibit resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy; administered orally.

alendronate

/alen·dro·nate/ (ah-len´dro-nāt) a bisphosphonate calcium-regulating agent used in the form of the sodium salt to inhibit the resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy.

alendronate

(ə-lĕn′drə-nāt′)
n.
A bisphosphonate drug, C4H13NO7P2, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.

alendronate

a bone-resorption inhibitor.
indications This drug is used to treat osteoporosis in postmenopausal women and Paget's disease.
contraindication Known hypersensitivity to biphosphonates prohibits the use of this drug.
adverse effects Side effects include anemia, hypokalemia, hypomagnesemia, hypophosphatemia, osteonecrosis of the jaw, abdominal pain, anorexia, constipation, nausea, vomiting, bone pain, hypertension, urinary tract infection, and fluid overload.

alendronate

A biphosphonate used to treat postmenopausal osteoporosis and Paget’s disease of bone. Alendronate reduces vertebral fractures by 48% and other fractures by 21%, increases bone density by 9% and density of the hip bones by 6% over 3 years of therapy.

Adverse effects
Nausea, stomach pain, constipation, diarrhoea, bloating, headaches, dizziness, swelling of joints (especially of hands and feet).

Mechanism of action
Marked inhibition of bone resorption by inhibiting osteoclastic activity and number of osteoclasts by reducing recruitment, and increasing apoptosis.

alendronate

Fosamax® Endocrinology A biphosphonate used to treat postmenopausal osteoporosis and Paget's disease of bone. See Osteoporosis. Cf Salmon calcitonin.

alendronate

A drug used in the prevention and treatment of post-menopausal OSTEOPOROSIS. A brand name is Fosamax.

Alendronate

A nonhormonal drug used to treat osteoporosis in postmenopausal women.
Mentioned in: Osteoporosis

alendronate

(ă-lendrŏ-nāt)
A bisphosphonate drug used to treat osteoporosis.
[coined term based on parts of the chemical name]
References in periodicals archive ?
Taken just once a week, strawberry flavored BINOSTO is a buffered effervescent solution that can help patients with swallowing difficulties be more compliant and decrease the risks of disabling fractures.
BINOSTO will be available in packs of four and 12 tablets.
Mission Pharmacal anticipates that BINOSTO will be commercially available in the third quarter of 2012.
Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, BINOSTO has the potential to improve long-term patient compliance and tolerability, thereby decreasing the risks of disabling fractures.
EffRx Pharmaceuticals SA also announces that it will regain the rights to BINOSTO / Steovess (EX101) in territories outside of North America.
EffRx CEO, Christer Rosen adds, "We believe Mission is the logical choice for bringing BINOSTO to the United States and Canadian markets.
We look forward to building strategic partnerships that will ensure BINOSTO is widely promoted and available throughout the United States and Canada.
Patients should be instructed that if they develop symptoms of esophageal disease (such as difficulty or pain upon swallowing, retrosternal pain, or new or worsening heartburn) they should stop taking BINOSTO and consult their physician.
for the first two of four episodes of the "Balancing Act" which also will feature discussions of osteoporosis and a treatment option, BINOSTO.